S&P 500   3,941.48 (-1.53%)
DOW   32,059.85 (-1.54%)
QQQ   312.09 (+0.56%)
AAPL   159.54 (+0.16%)
MSFT   275.90 (+0.77%)
META   203.27 (+0.55%)
GOOGL   105.67 (+0.71%)
AMZN   100.21 (-0.40%)
TSLA   196.34 (-0.63%)
NVDA   272.70 (+4.09%)
NIO   9.31 (+0.43%)
BABA   84.70 (+1.19%)
AMD   100.52 (+4.78%)
T   18.58 (+0.22%)
F   11.76 (+0.34%)
MU   59.66 (+1.76%)
CGC   1.92 (-2.79%)
GE   91.18 (-1.08%)
DIS   96.87 (+0.34%)
AMC   4.53 (+2.72%)
PFE   40.42 (-0.59%)
PYPL   76.15 (-0.74%)
NFLX   300.91 (-1.60%)
S&P 500   3,941.48 (-1.53%)
DOW   32,059.85 (-1.54%)
QQQ   312.09 (+0.56%)
AAPL   159.54 (+0.16%)
MSFT   275.90 (+0.77%)
META   203.27 (+0.55%)
GOOGL   105.67 (+0.71%)
AMZN   100.21 (-0.40%)
TSLA   196.34 (-0.63%)
NVDA   272.70 (+4.09%)
NIO   9.31 (+0.43%)
BABA   84.70 (+1.19%)
AMD   100.52 (+4.78%)
T   18.58 (+0.22%)
F   11.76 (+0.34%)
MU   59.66 (+1.76%)
CGC   1.92 (-2.79%)
GE   91.18 (-1.08%)
DIS   96.87 (+0.34%)
AMC   4.53 (+2.72%)
PFE   40.42 (-0.59%)
PYPL   76.15 (-0.74%)
NFLX   300.91 (-1.60%)
S&P 500   3,941.48 (-1.53%)
DOW   32,059.85 (-1.54%)
QQQ   312.09 (+0.56%)
AAPL   159.54 (+0.16%)
MSFT   275.90 (+0.77%)
META   203.27 (+0.55%)
GOOGL   105.67 (+0.71%)
AMZN   100.21 (-0.40%)
TSLA   196.34 (-0.63%)
NVDA   272.70 (+4.09%)
NIO   9.31 (+0.43%)
BABA   84.70 (+1.19%)
AMD   100.52 (+4.78%)
T   18.58 (+0.22%)
F   11.76 (+0.34%)
MU   59.66 (+1.76%)
CGC   1.92 (-2.79%)
GE   91.18 (-1.08%)
DIS   96.87 (+0.34%)
AMC   4.53 (+2.72%)
PFE   40.42 (-0.59%)
PYPL   76.15 (-0.74%)
NFLX   300.91 (-1.60%)
S&P 500   3,941.48 (-1.53%)
DOW   32,059.85 (-1.54%)
QQQ   312.09 (+0.56%)
AAPL   159.54 (+0.16%)
MSFT   275.90 (+0.77%)
META   203.27 (+0.55%)
GOOGL   105.67 (+0.71%)
AMZN   100.21 (-0.40%)
TSLA   196.34 (-0.63%)
NVDA   272.70 (+4.09%)
NIO   9.31 (+0.43%)
BABA   84.70 (+1.19%)
AMD   100.52 (+4.78%)
T   18.58 (+0.22%)
F   11.76 (+0.34%)
MU   59.66 (+1.76%)
CGC   1.92 (-2.79%)
GE   91.18 (-1.08%)
DIS   96.87 (+0.34%)
AMC   4.53 (+2.72%)
PFE   40.42 (-0.59%)
PYPL   76.15 (-0.74%)
NFLX   300.91 (-1.60%)
NASDAQ:TNDM

Tandem Diabetes Care - TNDM Stock Forecast, Price & News

$42.87
-0.84 (-1.92%)
(As of 03/22/2023 03:39 PM ET)
Add
Compare
Today's Range
$42.51
$44.00
50-Day Range
$35.86
$45.04
52-Week Range
$33.51
$123.96
Volume
526,055 shs
Average Volume
1.30 million shs
Market Capitalization
$2.77 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$63.17

Tandem Diabetes Care MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.56 Rating Score
Upside/​Downside
47.3% Upside
$63.17 Price Target
Short Interest
Bearish
9.75% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.64
Upright™ Environmental Score
News Sentiment
1.31mentions of Tandem Diabetes Care in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$411,900 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.97) to ($0.63) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.60 out of 5 stars

Medical Sector

97th out of 983 stocks

Surgical & Medical Instruments Industry

10th out of 100 stocks


TNDM stock logo

About Tandem Diabetes Care (NASDAQ:TNDM) Stock

Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its flagship product, t:slim X2 Insulin Delivery System, operates as a small insulin pump. The company was founded by Paul M. DiPerna on January 27, 2006, and is headquartered in San Diego, CA.

Receive TNDM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tandem Diabetes Care and its competitors with MarketBeat's FREE daily newsletter.

TNDM Stock News Headlines

Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
Tandem Diabetes Care (NASDAQ:TNDM) Trading Up 7.5%
Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
Tandem Diabetes Care PT Lowered to $71 at Barclays
Tandem Diabetes (TNDM) Q4 Earnings Beat, Gross Margin Dips
Tandem Diabetes Care Reports Q4 Preliminary Sales
See More Headlines
Receive TNDM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tandem Diabetes Care and its competitors with MarketBeat's FREE daily newsletter.

TNDM Company Calendar

Last Earnings
2/22/2023
Today
3/22/2023
Next Earnings (Estimated)
5/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TNDM
Fax
N/A
Employees
2,600
Year Founded
2006

Price Target and Rating

Average Stock Price Forecast
$63.17
High Stock Price Forecast
$130.00
Low Stock Price Forecast
$40.00
Forecasted Upside/Downside
+44.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.56
Research Coverage
9 Analysts

Profitability

Net Income
$-94,590,000.00
Pretax Margin
-11.59%

Debt

Sales & Book Value

Annual Sales
$801.22 million
Book Value
$6.84 per share

Miscellaneous

Free Float
63,108,000
Market Cap
$2.82 billion
Optionable
Optionable
Beta
0.85

Social Links


Key Executives

  • John F. SheridanJohn F. Sheridan
    President, Chief Executive Officer & Director
  • David B. Berger
    Chief Operating Officer, EVP & Assistant Secretary
  • Leigh A. VossellerLeigh A. Vosseller
    CFO, Treasurer, Principal Accounting Officer & EVP
  • Michael Michaud
    Vice President-Research & Development
  • Peter Rossiter
    Vice President-Information Technology













TNDM Stock - Frequently Asked Questions

Should I buy or sell Tandem Diabetes Care stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tandem Diabetes Care in the last twelve months. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TNDM shares.
View TNDM analyst ratings
or view top-rated stocks.

What is Tandem Diabetes Care's stock price forecast for 2023?

9 brokerages have issued 12-month target prices for Tandem Diabetes Care's shares. Their TNDM share price forecasts range from $40.00 to $130.00. On average, they anticipate the company's share price to reach $63.17 in the next twelve months. This suggests a possible upside of 44.5% from the stock's current price.
View analysts price targets for TNDM
or view top-rated stocks among Wall Street analysts.

How have TNDM shares performed in 2023?

Tandem Diabetes Care's stock was trading at $44.95 at the beginning of 2023. Since then, TNDM stock has decreased by 2.8% and is now trading at $43.71.
View the best growth stocks for 2023 here
.

When is Tandem Diabetes Care's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our TNDM earnings forecast
.

How were Tandem Diabetes Care's earnings last quarter?

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) released its earnings results on Wednesday, February, 22nd. The medical device company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.02) by $0.01. The medical device company earned $223.45 million during the quarter, compared to analysts' expectations of $221.99 million. Tandem Diabetes Care had a negative trailing twelve-month return on equity of 10.88% and a negative net margin of 11.81%. The firm's quarterly revenue was up 6.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.16 earnings per share.

When did Tandem Diabetes Care's stock split?

Tandem Diabetes Care shares reverse split on Tuesday, October 10th 2017. The 1-10 reverse split was announced on Monday, October 9th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 9th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What guidance has Tandem Diabetes Care issued on next quarter's earnings?

Tandem Diabetes Care issued an update on its FY 2023 earnings guidance on Wednesday, February, 22nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $885.00 million-$900.00 million, compared to the consensus revenue estimate of $891.55 million.

What is John Sheridan's approval rating as Tandem Diabetes Care's CEO?

11 employees have rated Tandem Diabetes Care Chief Executive Officer John Sheridan on Glassdoor.com. John Sheridan has an approval rating of 88% among the company's employees.

What other stocks do shareholders of Tandem Diabetes Care own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tandem Diabetes Care investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Micron Technology (MU), DexCom (DXCM), Netflix (NFLX), Block (SQ), Roku (ROKU), Lululemon Athletica (LULU) and PayPal (PYPL).

What is Tandem Diabetes Care's stock symbol?

Tandem Diabetes Care trades on the NASDAQ under the ticker symbol "TNDM."

Who are Tandem Diabetes Care's major shareholders?

Tandem Diabetes Care's stock is owned by many different institutional and retail investors. Top institutional shareholders include Eminence Capital LP (4.33%), Stephens Investment Management Group LLC (1.53%), Two Sigma Advisers LP (1.49%), Geode Capital Management LLC (1.42%), Marshall Wace LLP (1.37%) and Two Sigma Investments LP (1.37%). Insiders that own company stock include Brian B Hansen, Brian B Hansen, Christopher J Twomey, Christopher J Twomey, David B Berger, Dick Allen, Elizabeth Anne Gasser, James Leal, John F Sheridan, Kathleen Mcgroddy-Goetz, Kim D Blickenstaff, Leigh Vosseller, Mark Reinstra, Rebecca B Robertson, Rebecca B Robertson and Susan Morrison.
View institutional ownership trends
.

How do I buy shares of Tandem Diabetes Care?

Shares of TNDM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tandem Diabetes Care's stock price today?

One share of TNDM stock can currently be purchased for approximately $43.71.

How much money does Tandem Diabetes Care make?

Tandem Diabetes Care (NASDAQ:TNDM) has a market capitalization of $2.82 billion and generates $801.22 million in revenue each year. The medical device company earns $-94,590,000.00 in net income (profit) each year or ($1.48) on an earnings per share basis.

How many employees does Tandem Diabetes Care have?

The company employs 2,600 workers across the globe.

How can I contact Tandem Diabetes Care?

Tandem Diabetes Care's mailing address is 11075 ROSELLE STREET, San Diego CA, 92121. The official website for the company is www.tandemdiabetes.com. The medical device company can be reached via phone at (858) 366-6900 or via email at smorrison@tandemdiabetes.com.

This page (NASDAQ:TNDM) was last updated on 3/22/2023 by MarketBeat.com Staff